NovoCure Limited — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing reports annual financial results; it does not provide a clear standalone fourth-quarter revenue or profit figure. The company is a commercial-stage oncology business focused on tumor treating fields (TTFields), marketed as Optune for glioblastoma (GBM).
Business context and operating progress
In October 2015, NovoCure received FDA approval to market Optune with temozolomide for adults with newly diagnosed GBM and began marketing for this indication in the United States, Germany and Switzerland. Optune was also marketed for recurrent GBM in Japan. The company received a CE mark for its smaller, lighter second-generation system in October and filed a U.S. PMA supplement in December; Japan’s review of Optune for newly diagnosed GBM was also pending.
Fourth-quarter demand increased following the U.S. approval: 557 prescriptions were received, up 109% from the prior-year quarter (499 in the U.S. and 58 outside the U.S.). For full-year 2015, prescriptions totaled 1,777, up 151%; the reported prescription fill rate was 73%. Active patients reached 605 at year-end, up 169% from 2014.
Financial performance
| Metric (USD millions, except per-share data) | 2015 | 2014 | Change |
|---|---|---|---|
| Net revenue | 33.1 | 15.5 | +114% |
| Cost of revenue | 20.6 | 10.0 | +105% |
| Gross profit | 12.5 | 5.5 | +129% |
| Gross margin | 37.7% | 35.2% | +2.5 percentage points |
| Operating expenses | 116.5 | 85.6 | +36% |
| Operating loss | (104.0) | (80.2) | Loss widened |
| Net loss | (111.6) | (80.7) | Loss widened |
| Basic and diluted loss per share | $(3.67) | $(6.46) | — |
Revenue growth was driven primarily by U.S. commercial sales, reflecting more trained centers and demand following EF-14 trial results and the newly diagnosed GBM approval. Sales and marketing expense rose 84% to $38.9 million, largely to support the launch; research, development and clinical trial expense increased 8% to $43.7 million. General and administrative expense increased 41% to $33.9 million. Revenue is recognized when cash is collected because the company said it lacked sufficient payer collection history to estimate amounts reliably.
Net cash used in operating activities was $99.9 million, versus $74.2 million in 2014. Investing activities used $115.3 million, mainly reflecting purchases of short-term investments, property and equipment, and field equipment. Financing activities provided $277.0 million, including IPO proceeds, preferred-share proceeds and loan borrowings. Cash and cash equivalents were $119.4 million and short-term investments were $150.0 million at year-end; working capital was $265.3 million.
Outstanding principal under the term loan was $25.2 million at year-end, bearing 10% annual interest and due in January 2020. Up to a further $75.0 million was available under the facility through June 30, 2016, subject to its terms. The loan is secured by substantially all company assets and includes a minimum-liquidity covenant and net-sales requirements; NovoCure reported compliance at year-end. Management said available cash and investments were expected to fund operations for at least 12 months under its existing plan.
Outlook, risks and notable items
- Management expected operating losses and significant expenses to continue for at least several years, with research, clinical, commercialization and administrative spending expected to rise. It stated that substantial revenue growth would be required for profitability and that additional capital may be needed.
- Planned development included trials or programs in brain metastases, NSCLC, pancreatic, ovarian and mesothelioma cancers. The filing described proposed trial timing as expectations, subject to regulatory review, enrollment and other uncertainties.
- The principal commercial risks include dependence on Optune and GBM, market adoption and patient adherence, reimbursement and payer collections, and Medicare fee-for-service coverage. Medicare had denied claims to date; appeals were ongoing. The company reported positive commercial-payer coverage policies and approximately 98% coverage among U.S. active patients with commercial or privately administered plans.
- Manufacturing depends on third parties, including a single-source supplier for ceramic transducer-array components. Delays, quality issues or inability to qualify an alternate source could disrupt supply.
- Cash-based revenue recognition and a four-to-five-month average U.S. collection period create collection and timing uncertainty. Two payers represented 17% and 8% of 2015 revenue, respectively.
- A 2015 settlement concerning potential intellectual-property disputes included $5.5 million payable upon reaching a cumulative-sales milestone or a specified merger or asset transaction. The filing reported no material pending legal proceedings.
- The company raised $157.5 million net from its October 2015 IPO and $94.6 million net from its Series J financing. The IPO converted preferred shares into ordinary shares and increased the year-end ordinary share count substantially.
For newly diagnosed GBM, the cited EF-14 analysis reported median progression-free survival of 7.2 months with TTFields plus temozolomide versus 4.0 months with temozolomide alone, and median overall survival of 20.5 versus 15.6 months in the as-treated analysis. Reported skin reactions were the notable added toxicity; the filing’s trial findings are not a substitute for assessing subsequent evidence or real-world outcomes.
Important facts for investors to verify
- Latest Optune prescription, fill-rate, active-patient and treatment-duration trends, including the conversion of prescriptions into paying patients.
- Actual payer collections, revenue-recognition judgments, Medicare appeal status, and the impact of financial assistance and discounts on realized revenue.
- Cash burn, liquidity-covenant headroom, remaining loan availability and future financing needs.
- Progress and regulatory status of the next-generation Optune system and clinical programs, compared with management’s stated timelines.
- Supply-chain resilience, including qualification of an alternate ceramic-disc supplier, and the contingent Technion payment trigger.